Plasma Amiloid β42 in Patients with Obstructive Sleep Apnea before and after CPAP-Therapy: Pilot Study

ORIGINAL ARTICLE
Irina Madaeva, Natalya Semenova, Erdem Ukhinov, Nadezhda Kurashova, Leonid Sholohov, Sergey I. Kolesnikov, Lyubov I. Kolesnikova

 
International Journal of Biomedicine. 2019;9(3):205-209.
DOI: 10.21103/Article9(3)_OA3
Originally published September 15, 2019  

Abstract: 

The aim of this pilot research was to assess the sleep fragmentation influence on amyloid β42 (Aβ42) plasma levels before and after СPAP in patients with obstructive sleep apnea (OSA).
Materials and Methods: The study involved 24 patients (mean age of 52.5±2.7 years) with OSA and 20 persons without OSA (mean age of 49.1±8.2 years). All participants underwent overnight polysomnography, The Aβ42 level was determined in blood plasma by an immunoassay method. Patients with OSA were treated with auto-CPAP for 3 months.
Results: The research showed the following results in patients with OSA before CPAP, as compared to control: sleep fragmentation 1–2 times, increases in non-rapid eye movement sleep stage by 60% (P<0.05) and arousal index by 55% (P<0.05), and decreases in  slow-wave sleep duration by 40% (P<0.05) and rapid-eye-movement sleep by 43% (P<0.05). After CPAP-therapy, a decrease in arousal index by 40% (P<0.05) and apnea/hypopnea index (P<0.05), and increases in oxygen saturation by 17% (P<0.05), the slow-wave sleep duration by 56% (P<0.05) and rapid-eye-movement sleep by 55% (P<0.05) were found. Aβ42 levels were significantly lower in the group with OSA before CPAP-therapy, as compared to the control group and the group with OSA after CPAP-therapy (P<0.05). There were no differences in Aβ42 levels after treatment between control and main group.
Conclusion: Moderate and severe OSA is associated with a decrease in Aβ42 plasma level. CPAP-therapy leads to increase this peptide in blood plasma.

Keywords: 
obstructive sleep apnea • continuous positive airway pressure • polysomnography
References: 
  1. Yamagishi K, Ohira T, Nakano H, Bielinski SJ, Sakurai S, Imano H, et al. Cross-cultural comparison of the sleep-disordered breathing prevalence among Americans and Japanese. Eur Respir J. 2010;36(2):379-84. doi: 10.1183/09031936.00118609.
  2. Sforza E, Roche F, Thomas-Anterion C, Kerleroux J, Beauchet O, Celle S, et al. Cognitive function and sleep related breathing disorders in a healthy elderly population: the SYNAPSE study. Sleep. 2010;33(4):515-21.
  3. Hrubos-Strøm H, Nordhus IH, Einvik G, Randby A, Omland T, Sundet K, et al. Obstructive sleep apnea, verbal memory, and executive function in a community-based high-risk population identified by the Berlin Questionnaire Akershus Sleep Apnea Project. Sleep Breath. 2012;16(1):223-31. doi: 10.1007/s11325-011-0493-1.
  4. Nikodemova M, Finn L, Mignot E, Salzieder N, Peppard PE. Association of sleep disordered breathing and cognitive deficit in APOE ε4 carriers. Sleep. 2013 Jun 1;36(6):873-80. doi: 10.5665/sleep.2714.
  5. Martin MS, Sforza E, Roche F, Barthélémy JC, Thomas-Anterion C; PROOF study group. Sleep breathing disorders and cognitive function in the elderly: an 8-year follow-up study. the proof-synapse cohort. Sleep. 2015;38(2):179-87. doi: 10.5665/sleep.4392.
  6. Madaeva I, Berdina O, Semenova N, Madaev V, Kolesnikova L. Erectile dysfunction and sleep apnea syndrome are risk factors of cardiovascular diseases. European Journal of Preventive Cardiology. 2017;24(S1):S288.
  7. Emamian F, Khazaie H, Tahmasian M, Leschziner GD, Morrell MJ, Hsiung GY, et al. The Association Between Obstructive Sleep Apnea and Alzheimer's Disease: A Meta-Analysis Perspective. Front Aging Neurosci. 2016;8:78. doi: 10.3389/fnagi.2016.00078.
  8. Liguori C, Mercuri NB, Izzi F, Romigi A, Cordella A, Sancesario G, Placidi F. Obstructive Sleep Apnea is Associated With Early but Possibly Modifiable Alzheimer's Disease Biomarkers Changes. Sleep. 2017;40(5). doi: 10.1093/sleep/zsx011.
  9. Ju YE, Lucey BP, Holtzman DM. Sleep and Alzheimer disease pathology--a bidirectional relationship. Nat Rev Neurol. 2014;10(2):115-9. doi: 10.1038/nrneurol.2013.269.
  10. Lucey BP, McCullough A, Landsness EC, Toedebusch CD, McLeland JS, Zaza AM, et al. Reduced non-rapid eye movementsleep is associated with tau pathology in early Alzheimer's disease. Sci Transl Med. 2019;11(474). pii: eaau6550. doi: 10.1126/scitranslmed.aau6550.
  11. Nussbaum JM, Seward ME, Bloom GS. Alzheimer disease: a tale of two prions. Prion. 2013;7(1):14-9. doi: 10.4161/pri.22118.
  12. Pesaresi M, Lovati C, Bertora P, Mailland E, Galimberti D, Scarpini E, et al. Plasma levels of beta-amyloid (1-42) in Alzheimer's disease and mild cognitive impairment. Neurobiol Aging. 2006;27(6):904-5.
  13. Kheirandish-Gozal L, Philby MF, Alonso-Álvarez ML, Terán-Santos J, Gozal D. Biomarkers of Alzheimer Disease in Children with Obstructive Sleep Apnea: Effect of Adenotonsillectomy. Sleep. 2016;39(6):1225-32. doi: 10.5665/sleep.5838..
  14. Yang Y, Giau VV, An SSA, Kim S. Plasma Oligomeric Beta Amyloid in Alzheimer's Disease with History of Agent Orange Exposure. Dement Neurocogn Disord. 2018;17(2):41-49. doi: 10.12779/dnd.2018.17.2.41.
  15. Park JC, Han SH, Yi D, Byun MS, Lee JH, Jang S, et al. Plasma tau/amyloid-β1-42 ratio predicts brain tau deposition and neurodegeneration in Alzheimer's disease. Brain. 2019;142(3):771-786. doi: 10.1093/brain/awy347.
  16. Roher AE, Esh CL, Kokjohn TA, Castaño EM, Van Vickle GD, Kalback WM, et al. Amyloid beta peptides in human plasma and tissues and their significance for Alzheimer's disease. Alzheimers Dement. 2009;5(1):18-29. doi: 10.1016/j.jalz.2008.10.004.
  17. Kapur VK, Auckley DH, Chowdhuri S, Kuhlmann DC, Mehra R, Ramar K, Harrod CG. Clinical Practice Guideline for Diagnostic Testing for Adult Obstructive Sleep Apnea: An American Academy of Sleep Medicine Clinical Practice Guideline. J Clin Sleep Med. 2017;13(3):479-504. doi: 10.5664/jcsm.6506.
  18. Benveniste H, Liu X, Koundal S, Sanggaard S, Lee H, Wardlaw J. The Glymphatic System and Waste Clearance with Brain Aging: A Review. Gerontology. 2019;65(2):106-119. doi: 10.1159/000490349.
  19. Xie L, Kang H, Xu Q, Chen MJ, Liao Y, Thiyagarajan M, et al. Sleep drives metabolite clearance from the adult brain. Science. 2013;342(6156):373-7. doi: 10.1126/science.1241224.
  20. Eugene AR, Masiak J. The Neuroprotective Aspects of Sleep. MEDtube Sci. 2015 Mar;3(1):35-40.
  21. Bushey D, Tononi G, Cirelli C. Sleep and synaptic homeostasis: structural evidence in Drosophila. Science. 2011;332(6037):1576-81. doi: 10.1126/science.1202839.
  22. Cirelli C, Tononi G. Sleep. 2015 Jan 1;38(1):161-2. doi: 10.5665/sleep.4348. Sleep and synaptic homeostasis.
  23. Lim MM, Gerstner JR, Holtzman DM. The sleep-wake cycle and Alzheimer's disease: what do we know? Neurodegener Dis Manag. 2014;4(5):351-62. doi: 10.2217/nmt.14.33.
  24. Lim DC, Pack AI. Obstructive sleep apnea and cognitive impairment: addressing the blood-brain barrier. Sleep Med Rev. 2014;18(1):35-48. doi: 10.1016/j.smrv.2012.12.003.
  25. Baronio D, Martinez D, Fiori CZ, Bambini-Junior V, Forgiarini LF, Pase da Rosa D, et al. Altered aquaporins in the brains of mice submitted to intermittent hypoxia model of sleep apnea. Respir Physiol Neurobiol. 2013;185(2):217-21. doi: 10.1016/j.resp.2012.10.012.
  26. Kim LJ, Martinez D, Fiori CZ, Baronio D, Kretzmann NA, Barros HM. Hypomyelination, memory impairment, and blood-brain barrier permeability in a model of sleep apnea. Brain Res. 2015;1597:28-36. doi: 10.1016/j.brainres.2014.11.052.
  27. Yaffe K, Weston A, Graff-Radford NR, Satterfield S, Simonsick EM, Younkin SG, et al. Association of plasma beta-amyloid level and cognitive reserve with subsequent cognitive decline. JAMA. 2011;305(3):261-6. doi: 10.1001/jama.2010.1995.
  28. Nalivaeva NN, Turner AJ. Role of Ageing and Oxidative Stress in Regulation of Amyloid-Degrading Enzymes and Development of Neurodegeneration. Curr Aging Sci. 2017;10(1):32-40.
  29. Fisk L, Nalivaeva NN, Boyle JP, Peers CS, Turner AJ. Effects of hypoxia and oxidative stress on expression of neprilysin in human neuroblastoma cells and rat cortical neurones and astrocytes. Neurochem Res. 2007;32(10):1741-8
  30. Wang Z, Yang D, Zhang X, Li T, Li J, Tang Y, Le W. Hypoxia-induced down-regulation of neprilysin by histone modification in mouse primary cortical and hippocampal neurons. PLoS One. 2011;6(4):e19229. doi: 10.1371/journal.pone.0019229.

Download Article
Received July 12, 2019.
Accepted August 21, 2019.
©2019 International Medical Research and Development Corporation.